DataMeds AI annual return on equity
2024
DataMeds AI Return on Equity (ROE) Growth & History (MEDS)
DataMeds AI's return on equity was −357.65% for fiscal 2024.
View full DataMeds AI company overviewDataMeds AI annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −357.65% | — |
DataMeds AI quarterly return on equity
Q4.24
Q1.25
Q2.25
Q3.25
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q3 2025 | 2025-09-30 | −893.32% | — |
| Q2 2025 | 2025-06-30 | −247.86% | — |
| Q1 2025 | 2025-03-31 | −578.44% | — |
| Q4 2024 | 2024-12-31 | −225.96% | — |
DataMeds AI return on equity trends
The latest reported quarter, Q3 2025, shows −893.32%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review DataMeds AI source filings ↗